Gabriëla Wright

1.3k total citations
20 papers, 1.1k citations indexed

About

Gabriëla Wright is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Gabriëla Wright has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Immunology. Recurrent topics in Gabriëla Wright's work include Cancer-related Molecular Pathways (4 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Mechanisms and Therapy (3 papers). Gabriëla Wright is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Mechanisms and Therapy (3 papers). Gabriëla Wright collaborates with scholars based in United States, Puerto Rico and China. Gabriëla Wright's co-authors include Kenneth L. Wright, W. Douglas Cress, Yihong Ma, Rosalyn Irby, Richard Jove, Jiangdong Chen, James G. Karras, Drew M. Pardoll, Mei Huang and Guilian Niu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Gabriëla Wright

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriëla Wright United States 15 636 450 268 195 130 20 1.1k
Suhu Liu United States 18 946 1.5× 476 1.1× 287 1.1× 333 1.7× 76 0.6× 34 1.4k
Steven A. Enkemann United States 18 783 1.2× 414 0.9× 185 0.7× 246 1.3× 110 0.8× 31 1.3k
Samuel Wormald Australia 7 369 0.6× 408 0.9× 269 1.0× 141 0.7× 104 0.8× 8 802
Susan E. Morgan-Lappe United States 11 827 1.3× 406 0.9× 171 0.6× 190 1.0× 60 0.5× 20 1.1k
Yun Hee Kang South Korea 18 535 0.8× 332 0.7× 258 1.0× 212 1.1× 72 0.6× 44 1.0k
Emanuel Petricoin United States 10 669 1.1× 817 1.8× 361 1.3× 301 1.5× 78 0.6× 12 1.3k
Claudia P. Miller United States 16 722 1.1× 364 0.8× 143 0.5× 185 0.9× 54 0.4× 23 1.1k
Alok R. Singh United States 16 494 0.8× 216 0.5× 197 0.7× 177 0.9× 57 0.4× 25 858
Magdalena Bachvarova Canada 22 718 1.1× 245 0.5× 229 0.9× 255 1.3× 54 0.4× 35 1.2k
Hengrui Zhu United States 14 895 1.4× 458 1.0× 262 1.0× 186 1.0× 40 0.3× 22 1.2k

Countries citing papers authored by Gabriëla Wright

Since Specialization
Citations

This map shows the geographic impact of Gabriëla Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriëla Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriëla Wright more than expected).

Fields of papers citing papers by Gabriëla Wright

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriëla Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriëla Wright. The network helps show where Gabriëla Wright may publish in the future.

Co-authorship network of co-authors of Gabriëla Wright

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriëla Wright. A scholar is included among the top collaborators of Gabriëla Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriëla Wright. Gabriëla Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wright, Gabriëla, Bhaswati Sarcar, Edna R. Gordián, et al.. (2021). CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS ONE. 16(6). e0252927–e0252927. 4 indexed citations
2.
Wright, Gabriëla, et al.. (2020). Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochemical and Biophysical Research Communications. 534. 773–779. 19 indexed citations
3.
Sarcar, Bhaswati, Gabriëla Wright, Lily L. Remsing Rix, et al.. (2019). Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. FEBS Open Bio. 9(10). 1689–1704. 4 indexed citations
4.
Wright, Gabriëla, Volha A. Golubeva, Lily L. Remsing Rix, et al.. (2017). Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. ACS Chemical Biology. 12(7). 1883–1892. 57 indexed citations
5.
Woods, Nicholas T., Gabriëla Wright, Lily L. Remsing Rix, et al.. (2016). PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Molecular Cancer Therapeutics. 15(7). 1669–1681. 21 indexed citations
6.
Knezevic, Claire E., Gabriëla Wright, Lily L. Remsing Rix, et al.. (2016). Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell chemical biology. 23(12). 1490–1503. 77 indexed citations
7.
Kuenzi, Brent M., Lily L. Remsing Rix, Sateesh Kunigal, et al.. (2015). Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Cancer Research. 75(15_Supplement). 675–675. 1 indexed citations
8.
Rix, Lily L. Remsing, Brent M. Kuenzi, Yunting Luo, et al.. (2013). GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells. ACS Chemical Biology. 9(2). 353–358. 74 indexed citations
9.
Pan, Hongjie, Thomas O’Brien, Gabriëla Wright, et al.. (2013). Critical Role of the Tumor Suppressor Tuberous Sclerosis Complex 1 in Dendritic Cell Activation of CD4 T Cells by Promoting MHC Class II Expression via IRF4 and CIITA. The Journal of Immunology. 191(2). 699–707. 45 indexed citations
10.
Smith, Matthew A., Gabriëla Wright, Jian Wu, et al.. (2011). Positive Regulatory Domain I (PRDM1) and IRF8/PU.1 Counter-regulate MHC Class II Transactivator (CIITA) Expression during Dendritic Cell Maturation. Journal of Biological Chemistry. 286(10). 7893–7904. 48 indexed citations
11.
Zhang, X, X Chen, Jianhong Lin, et al.. (2011). Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 31(24). 3002–3008. 137 indexed citations
12.
Seidman, A. D., A M Bach, Andres Forero‐Torres, et al.. (2011). P1-14-01: Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.. Cancer Research. 71(24_Supplement). P1–14. 1 indexed citations
13.
14.
Ma, Yihong, Lü Chen, Gabriëla Wright, et al.. (2010). CDKN1C Negatively Regulates RNA Polymerase II C-terminal Domain Phosphorylation in an E2F1-dependent Manner. Journal of Biological Chemistry. 285(13). 9813–9822. 20 indexed citations
15.
Conlin, Alison, C. Hudis, A M Bach, et al.. (2009). Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1006–1006. 23 indexed citations
16.
Yanamandra, Niranjan, Robert Buzzeo, David Boulware, et al.. (2006). Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia. Clinical Cancer Research. 12(2). 591–599. 73 indexed citations
17.
Niu, Guilian, Kenneth L. Wright, Yihong Ma, et al.. (2005). Role of Stat3 in Regulating p53 Expression and Function. Molecular and Cellular Biology. 25(17). 7432–7440. 332 indexed citations
18.
Ghosh, Nilanjan, et al.. (2001). Positive Regulatory Domain I Binding Factor 1 Silences Class II Transactivator Expression in Multiple Myeloma Cells. Journal of Biological Chemistry. 276(18). 15264–15268. 59 indexed citations
19.
Ghosh, Nilanjan, et al.. (1999). A Novel Element and a TEF-2-like Element Activate the Major Histocompatibility Complex Class II Transactivator in B-lymphocytes. Journal of Biological Chemistry. 274(45). 32342–32350. 50 indexed citations
20.
Ostrer, Harry, et al.. (1989). Familial XX chromosomal maleness does not arise from a Y chromosomal translocation. The Journal of Pediatrics. 114(6). 977–982. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suhu Liu Breakdown of academic impact, for papers by Steven A. Enkemann Breakdown of academic impact, for papers by Samuel Wormald Breakdown of academic impact, for papers by Susan E. Morgan-Lappe Breakdown of academic impact, for papers by Yun Hee Kang Breakdown of academic impact, for papers by Emanuel Petricoin Breakdown of academic impact, for papers by Claudia P. Miller Breakdown of academic impact, for papers by Alok R. Singh Breakdown of academic impact, for papers by Magdalena Bachvarova Breakdown of academic impact, for papers by Hengrui Zhu
Rankless by CCL
2026